|
|
 |
|
 |
|
| 1 |
Arai T, Okato A, Yamada Y, Sugawara S, Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.N. Cancer Med. 2018 Apr 2. doi: 10.1002/cam4.1455. PMID:29608247
|
| 2 |
Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Matsuda T, Akakura K, Hata A, Ichikawa T.Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan.Int J Urol. 2018 Apr;25(4):373-378. doi: 10.1111/iju.13552.PMID:29648701
|
| 3 |
Sugiura M, Imamura Y, Kawamura K, Yamamoto S, Sazuka T, Nakamura K, Sakamoto S, Nagano H, Koide H, Tanaka T, Imamoto T, Komiya A, Ichikawa T. Contralateral adrenal width predicts the duration of prolonged post-surgical steroid replacement for subclinical Cushing syndrome. Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13566. PMID:29651813
|
| 4 |
Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, Kijima Y, Maemura K, Natsugoe S. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Cancer Sci. 2018 Jun;109(6):2013-2026. doi: 10.1111/cas.13610. Epub 2018 May 22. PMID:29660218
|
| 5 |
Shimazaki J, Chung LW, Zhau HE, Ichikawa T. Dr. Coffey's visionary contributions to urological research in China and Japan. Am J Clin Exp Urol. 2018 Apr 1;6(2):15-22. eCollection 2018. No abstract available. PMID:29666826
|
| 6 |
Yamada Y, Sakamoto S, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H. Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy. Asian J Androl. 2018 Sep-Oct;20(5):432-437. doi: 10.4103/aja.aja_24_18. PMID:29735818
|
| 7 |
Ken Wakai,Takanobu Utsumi, Kei Yoneda,Ryo Oka, Takumi Endo, Masashi Yano, Masaaki Fujimura,Naoto Kamiya, Nobuyuki Sekita, Kazuo Mikami, Isamu Sugano, Nobuyuki Hiruta,Hiroyoshi Suzuki Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor Int J Clin Oncol. 2018 Oct;23(5):957-964. doi: 10.1007/s10147-018-1299-y. Epub 2018 May 26. PMID: 29804156
|
| 8 |
Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N. Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. Oncotarget. 2018 Jun 1;9(42):26638-26658. doi: 10.18632/oncotarget.25410. eCollection 2018 Jun1. PMID:29928475
|
| 9 |
Yamada Y, Arai T, Kojima S, Sugawara S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N. Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance.Cancer Sci. 2018 Jul 3. doi: 10.1111/cas.13722. PMID:29968393
|
| 10 |
Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Ebner DK, Hayashi K, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors. Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. Cancer Sci. 2018 Sep;109(9):2873-2880. doi: 10.1111/cas.13727. Epub 2018 Sep 1.
PMID:29981249
|
| 11 |
Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Yamada Y, Arai T, Kita Y, Kijima Y, Mataki Y, Maemura K, Natsugoe S. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p. Oncotarget. 2018 Jun 22;9(48):28849-28865. doi: 10.18632/oncotarget.25599. eCollection 2018 Jun 22. PMID:29988949
|
| 12 |
Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, Kumamoto T, Sanada H, Suetsugu T, Inoue H. Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. J Hum Genet. 2018 Oct;63(10):1015-1028. doi: 10.1038/s10038-018-0497-9. Epub 2018 Aug 6.PMID:30082847
|
| 13 |
Yamada Y, Sugawara S, Arai T, Kojima S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N, Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation. Int J Urol. 2018 Aug 28. doi: 10.1111/iju.13783. PMID:30153702
|
| 14 |
Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N.
Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.
J Hum Genet. 2018 Sep 18. doi: 10.1038/s10038-018-0510-3.Epub 2018 Sep 18.
PMID:30228364
|
| 15 |
Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T. Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan. Int J Urol. 2018 Oct 11. doi: 10.1111/iju.13817. PMID:30308705
|
| 16 |
Uchida A, Seki N, Mizuno K, Misono S, Yamada Y, Kikkawa N, Sanada H, Kumamoto T, Suetsugu T, Inoue H. Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.Cancer Sci. 2019 Jan;110(1):420-432. doi: 10.1111/cas.13853. Epub 2018 Dec 6. PMID:30375717
|
| 17 |
Namekawa T, Imamoto T, Kato M, Komiya A, Ichikawa T. Vasovasostomy and vasoepididymostomy: Review of the procedures, outcomes, and predictors of patency and pregnancy over the last decade. Reprod Med Biol. 2018 May 22;17(4):343-355. doi: 10.1002/rmb2.12207. eCollection 2018 Oct. Review. PMID:30377390
|
| 18 |
Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p. Mol Oncol. 2018 Nov 15. doi: 10.1002/1878-0261.12405. Epub 2018 Dec 21. PMID:30444038
|
| 19 |
Shimonosono M, Idichi T, Seki N, Yamada Y, Arai T, Arigami T, Sasaki K, Omoto I, Uchikado Y, Kita Y, Kurahara H, Maemura K, Natsugoe S. Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR?145?3p on gene regulation. Int J Oncol. 2019 Feb;54(2):673-688. doi: 10.3892/ijo.2018.4657. Epub 2018 Dec 6. PMID:30535463
|
| 20 |
Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Hayashi K, Ebner DK, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors. Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma Oncotarget. 2019 Jan 1;10(1):76-81.doi:10.18632/oncotarget.26539. eCollection 2019 Jan 1. PMID:30713604
|
| 21 |
Wakabayashi S, Takaoka H, Miyauchi H, Sazuka T, Saito Y, Sugimoto K, Funabashi N, Ichikawa T, Matsubara H, Kobayashi Y. Usefulness of Renal Autotransplantation for Radiotherapy-induced Renovascular Hypertension. Intern Med. 2019 Feb 25. doi: 10.2169/internalmedicine.2001-18.PMID:30799345
|
| 22 |
Uchida A, Seki N, Mizuno K, Yamada Y, Misono S, Sanada H, Kikkawa N, Kumamoto T, Suetsugu T, Inoue H. Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma. Cancers (Basel). 2019 Feb 22;11(2). pii: E258. doi: 10.3390/cancers11020258. PMID: 30813343
|
| 23 |
Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N. Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p. Int J Urol. 2019 Feb 28. doi: 10.1111/iju.13911. Epub 2019 Feb 28. PMID:30818424
|
| 24 |
Yamada Y, Arai T, Kato M, Kojima S, Sakamoto S, Komiya A, Naya Y, Ichikawa T, Seki N. Role of pre-miR-532 (miR-532-5p and miR-532-3p) in regulation of gene expression and molecular pathogenesis in renal cell carcinoma. Am J Clin Exp Urol. 2019 Feb 18;7(1):11-30. eCollection 2019. PubMed PMID: 30906802; PubMed Central PMCID: PMC6420701.
|
| 25 |
Sugiyama M, Fujimura M, Nakamori H, Nishikawa R, Sakamoto S, Sekita N, Suzuki H, Mikami K, Ichikawa T. Repeated spontaneous migration of ureteral stent in hemiplegia patient during ureteral stone treatment. Urol Case Rep. 2019 Feb 21;24:100854. doi:10.1016/j.eucr.2019.100854. eCollection 2019 May.PMID:31211065
|
| 26 |
Asazawa K, Jitsuzaki M, Mori A, Ichikawa T, Shinozaki K, Yoshida A, Kawanami M, Kamiyama H. Validity and Reliability of the Japanese Version of theFertility Quality of Life (FertiQoL) Tool for Couples Undergoing FertilityTreatment. Open Journal of Nursing, 2018, 8, 616-628.
|
| 27 |
Yamada Y, Sakamoto S, et al, Extremely high PSA ( ?1000 ng/ml) predicts favorable response to AWS and alternative nonsteroidal antiandrogen therapy in metastatic prostate cancer. Asian J Androl 2018 in press
|
| 28 |
Sakamoto S, Xu M,. Kamada S, Yamada Y, Kitoh H, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Higher serum testosterone levels predict a favorable prognosis in Enzalutamide and Abiraterone treated castration resistant prostate cancer patients in Japanese men. Prostate Int. 2018 in press
|
|
|
|
|
|
|
|
|
|
|
|
|
